All Articles

I would like to extend a personal invitation to each of you to join our private AONN+ Facebook group.

As a survivor of homelessness, domestic abuse, and advanced-stage breast cancer, Gail Zahtz is no stranger to hardship. When things got so bad that she was told to simply “accept her situation,” she credits her navigator with saving her life by helping her find her own voice.

How Navigators Can Ease the Burden for Patients and Loved Ones

A recent review presents updated treatment strategies for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.

A recent study from the United Kingdom in younger adults with non–small-cell lung cancer found poor survival outcomes in patients without targetable mutations.

Based on positive results of the KRYSTAL-1 clinical trial, adagrasib was granted accelerated FDA approval for patients with non–small-cell lung cancer harboring the KRAS G12C mutation.

A recent study assessing the prognostic value of circulating tumor cells in patients with lung cancer found an association with poorer patient outcomes, with more pronounced effect on small-cell lung cancer.

When it comes to justifying the need for navigation resources, building a business case is a nonnegotiable, according to Lindsey Reed, MBA, BSN, RN, OCN, ONN-CG, director of navigation for Sarah Cannon in the HCA Midwest Division, and Nicole Centers, MBA, BSN, RN, OCN, CBCN, CN-BN, executive director of Oncology Service Line at Wellstar Healthcare System in Marietta, GA.

Whether we are displaying it or experiencing it, implicit bias is an unavoidable part of life, according to Stephanie L. Graff, MD, FACP, director of breast oncology at the Lifespan Cancer Institute.

Renal-cell carcinoma (RCC) is among the 10 most common cancers for men and women in the United States and has been shown to cause considerable burden in both patients and their caregivers.